RT @IUCancerCenter: Mohammad Issam Abu-Zaid (@DrM_AbuZaid), MD, Patrick Loehrer, MD, and their colleagues investigate the efficacy and safe…
172 followers
1,459 followers
Mohammad Issam Abu-Zaid (@DrM_AbuZaid), MD, Patrick Loehrer, MD, and their colleagues investigate the efficacy and safety of buparlisib, an oral pan-PI3K inhibitor, in relapsed or refractory thymomas in an article in Frontiers in Oncology. Learn more: http
17,538 followers
A phase II study of buparlisib in relapsed or refractory thymomas https://t.co/pcVLjA7CYt https://t.co/32fSkXPSlI
172 followers
RT @FrontOncology: 📄 A phase II study of buparlisib in relapsed or refractory #thymomas 👨⚕️👩⚕️ Mohammad I. Abu Zaid et al @DrM_AbuZaid…